Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer-Reference-Cited by-同舟云学术

Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer

Published:2020-03 Issue:1 Volume:1 Page:15-20
ISSN:2688-4526
Container-title:BJUI Compass
language:en
Short-container-title:BJUI Compass

Author:

Klocker Helmut¹^ORCID,Golding Bruno²,Weber Stephan³,Steiner Eberhard¹,Tennstedt Pierre⁴^ORCID,Keller Thomas³,Schiess Ralph²^ORCID,Gillessen Silke⁵,Horninger Wolfgang¹,Steuber Thomas⁴

Affiliation:

1. Department of Urology Medical University Innsbruck Innsbruck Austria

2. ProteoMediX AG Schlieren Switzerland

3. ACOMED Statistics Leipzig Germany

4. Martini Clinic Prostate Cancer Center University Hospital Hamburg‐Eppendorf Hamburg Germany

5. Medical Oncology Department Oncology Institute of Southern Switzerland Bellinzona Switzerland

Funder

ProteoMediX AG

Publisher

Wiley

Subject

Religious studies,Cultural Studies

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/bco2.8

Reference27 articles.

1. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases;Aksoy Y;Ann Clin Lab Sci,2004

2. Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with “gray” prostate-specific antigen levels at first biopsy: systematic review and meta-analysis

3. Guidelines EAU. Edn. presented at the EAU Annual Congress Barcelona 2019. Barcelona 2019. ISBN 978‐94‐92671‐04‐2.

4. Evidence for a Biopsy Derived Grade Artifact Among Larger Prostate Glands

5. Family history and probability of prostate cancer, differentiated by risk category: a nationwide population‐based study;Bratt O;J Natl Cancer Inst,2016

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Potential of Extracellular Matrix- and Integrin Adhesion Complex-Related Molecules for Prostate Cancer Biomarker Discovery;Biomedicines;2023-12-28

2. Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identification;Expert Review of Molecular Diagnostics;2023-11-13

3. Management Strategy for Prostate Imaging Reporting and Data System Category 3 Lesions;Current Urology Reports;2023-11-08

4. Biosensors for prostate cancer detection;Trends in Biotechnology;2023-10

5. Evaluation of Proclarix in the diagnostic work‐up of prostate cancer;BJUI Compass;2023-09-29